Literature DB >> 9100040

Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases.

A Koyama1, M Igarashi, M Kobayashi.   

Abstract

The Research Group on Progressive Renal Diseases conducted a national survey, in Japan, of cases of primary glomerulonephritis (GN) in 1985 and 1993. The results of the survey, reported here, revealed a high prevalence and relatively poor prognosis for immunoglobulin A nephropathy (IgAN). Using immunofluorescent microscopy, 47.2% of 1,063 patients were diagnosed as having IgAN; 62.8% of patients had diffuse mesangial proliferative GN, and focal mesangial proliferative GN was observed in 23.0%. Nearly 70% of the patients had no clinical symptoms, and the IgAN was detected by routine physical examination. The mean period of observation was 11.8 +/- 6.3 years. Renal survival rates for the 502 cases of IgAN, in which the start of dialysis and renal-related death were end points, were 96%, 85%, 75%, and 61% at 5, 10, 15, and 20 years, respectively, from the time of the detection of the earliest known renal abnormalities. Renal survival rates of patients with diffuse mesangial proliferative GN were 96%, 83%, 75%, and 59% at 5, 10, 15, and 20 years, respectively. At the end of the observation period, 20% of patients had improved, 45.8% showed no change, 13.5% had deteriorated, and 20.4% had renal-related death. The risk factors for renal failure by logistic multivariate analysis were serum creatinine concentration > or =1.4 mg/dL (relative risk, 3.5) and levels of urinary protein > or = +(dipstick) (relative risk, 6.4), determined at the time of biopsy. These parameters can be useful for assessing prognosis during the relatively advanced stages of this disease. It is important to note that a relatively high percentage of patients with IgAN progressed to end-stage renal failure even when their histologic findings comprised only minor glomerular abnormalities or focal proliferative changes.

Entities:  

Mesh:

Year:  1997        PMID: 9100040     DOI: 10.1016/s0272-6386(97)90333-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  111 in total

1.  Relationship between dietary protein intake and the changes in creatinine clearance and glomerular cross-sectional area in patients with IgA nephropathy.

Authors:  Toshikazu Wada; Toshiyuki Nakao; Hiroshi Matsumoto; Tomonari Okada; Yume Nagaoka; Hideaki Iwasawa; Asako Gondo; Ami Niwata; Yoshihiko Kanno
Journal:  Clin Exp Nephrol       Date:  2014-11-16       Impact factor: 2.801

2.  Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Tatsuya Shoji; Yoshitsugu Obi; Tomoko Namba; Harumi Kitamura; Tetsuya Kaneko; Noriyuki Okada; Hirotsugu Iwatani; Atsushi Yamauchi; Yoshiharu Tsubakihara; Enyu Imai; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

3.  Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy.

Authors:  Miho Tatematsu; Yoshinari Yasuda; Yoshiki Morita; Izumi Sakamoto; Kei Kurata; Tomohiko Naruse; Rhohei Yamamoto; Naotake Tsuboi; Waichi Sato; Enyu Imai; Seiichi Matsuo; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2012-05-23       Impact factor: 2.801

4.  Association of FOS-like antigen 1 promoter polymorphism with podocyte foot process effacement in immunoglobulin A nephropathy patients.

Authors:  Hae Jeong Park; Jong Woo Kim; Byoung-Soo Cho; Joo-Ho Chung
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

5.  Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010.

Authors:  Hitoshi Sugiyama; Hitoshi Yokoyama; Hiroshi Sato; Takao Saito; Yukimasa Kohda; Shinichi Nishi; Kazuhiko Tsuruya; Hideyasu Kiyomoto; Hiroyuki Iida; Tamaki Sasaki; Makoto Higuchi; Motoshi Hattori; Kazumasa Oka; Shoji Kagami; Tetsuya Kawamura; Tetsuro Takeda; Hiroshi Hataya; Yuichiro Fukasawa; Atsushi Fukatsu; Kunio Morozumi; Norishige Yoshikawa; Akira Shimizu; Hiroshi Kitamura; Yukio Yuzawa; Seiichi Matsuo; Yutaka Kiyohara; Kensuke Joh; Michio Nagata; Takashi Taguchi; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

6.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

7.  Treatment of IgA nephropathy of adults presented by nephrotic syndrome.

Authors:  Senija Rasić; Snjezana Uncanin; Kenana Aganović; Ismar Rasić; Jasminka Dzemidzić; Alma Muslimović
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

8.  Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy.

Authors:  Nobuo Tsuboi; Tetsuya Kawamura; Kentaro Koike; Hideo Okonogi; Keita Hirano; Akihiko Hamaguchi; Yoichi Miyazaki; Makoto Ogura; Kensuke Joh; Yasunori Utsunomiya; Tatsuo Hosoya
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 8.237

9.  Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy.

Authors:  Naoto Miura; Hirokazu Imai; Shogo Kikuchi; Shogo Hayashi; Masayuki Endoh; Tetsuya Kawamura; Yasuhiko Tomino; Kumiko Moriwaki; Hideyasu Kiyomoto; Kentaro Kohagura; Eiko Nakazawa; Eiji Kusano; Toshio Mochizuki; Shinsuke Nomura; Tamaki Sasaki; Naoki Kashihara; Jun Soma; Tadashi Tomo; Iwao Nakabayashi; Masaharu Yoshida; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

10.  Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

Authors:  Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich
Journal:  Kidney Int       Date:  2015-08-19       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.